Every Form 4 that Nexgel Inc Wt Exp 120126 (NXGLW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NXGLW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NXGLW filings page.
NEXGEL, INC. Chief Executive Officer and director Adam R. Levy was granted a stock option to purchase 160,000 shares of common stock at an exercise price of $0.647 per share on July 23, 2026. The option expires on July 23, 2031 and is held as direct ownership. Following this grant, Levy holds options covering 160,000 underlying shares.
The option vests over time: it becomes exercisable for 40,000 shares on December 31, 2026, and the remaining 120,000 shares vest in 36 monthly installments of 3,334 shares (with rounding adjustments) beginning January 31, 2027, in each case contingent on Levy’s continued employment with NEXGEL through the relevant vesting date. Any unvested portion will fully accelerate and become immediately exercisable upon a qualifying Change in Control under Levy’s executive employment agreement dated July 23, 2026.
NEXGEL, INC. Chief Executive Officer Adam R. Levy reported two open-market sales of the company’s Common Stock. He sold 6,000 shares on June 18, 2026 at a weighted average price of about $0.5921 per share, and 5,000 shares on June 23, 2026 at about $0.5933 per share. After these transactions, he directly holds 322,692 shares of NEXGEL common stock.
NEXGEL, INC. Chief Executive Officer Adam R. Levy reported an open-market sale of common stock. On June 11, 2026, he sold 3,000 shares at $0.6136 per share. After this transaction, he continues to directly hold 333,692 shares of NEXGEL common stock.
NEXGEL, INC. Chief Executive Officer Adam R. Levy reported open-market sales of company common stock. He sold 3,000 shares at $0.5936 per share on June 4 and 3,000 shares at $0.5470 per share on June 8. After these transactions, he directly holds 336,692 shares of NEXGEL common stock, indicating he retained the vast majority of his position.
NEXGEL, INC. Chief Executive Officer Adam R. Levy reported selling a total of 13,000 shares of Common Stock in open-market transactions over three days. He sold 3,000 shares at $0.5975 per share, 7,000 shares at a weighted average price of $0.6058 per share, and 3,000 shares at $0.6003 per share. Following these sales, he directly holds 344,692 shares of NEXGEL Common Stock, indicating these sales represent a relatively small portion of his overall position.
NEXGEL director Henry Scott Robert acquired new derivative securities linked to the company’s common stock. He received a Convertible Promissory Note with an original principal amount of $25,000, which is convertible into up to 41,667 shares of common stock at an initial conversion price of $0.60 per share.
He also received a Warrant to Purchase Common Stock for 20,834 shares at an initial exercise price of $0.80 per share. Both the note and warrant are exercisable at his option, subject to a 4.99% beneficial-ownership limitation and other specified conditions.
NEXGEL director Brian Joseph Kieser bought a $1,000,000 Convertible Promissory Note and received a large stock warrant as part of the same financing. The Note can be converted into up to 1,666,667 shares of common stock at $0.60 per share. The warrant is exercisable for 833,334 shares at $0.80 per share. Both instruments are convertible or exercisable at the holder’s option but are subject to a 4.99% beneficial-ownership limitation on NEXGEL’s outstanding common stock.
NEXGEL, INC. reported that Chief Executive Officer Adam R. Levy acquired derivative securities linked to its common stock. He received a Convertible Promissory Note with an original principal amount of $60,000, which is convertible into up to 100,000 shares of common stock at $0.60 per share. He also received a Warrant to Purchase Common Stock for 50,000 shares at an initial exercise price of $0.80 per share, issued as part of the consideration for purchasing the note. Both the note and warrant are exercisable at any time at his option, subject to a 4.99% beneficial-ownership limitation that restricts conversion or exercise if it would push ownership above that threshold.